Literature DB >> 29745876

The presence of staphylococcal superantigens in nasal swabs and correlation with activity of granulomatosis with polyangiitis in own material.

Justyna Fijołek1, Elzbieta Wiatr2, Violetta Petroniec3, Ewa Augustynowicz-Kopec3, Michal Bednarek4, Dariusz Gawryluk2, Magdalena Maria Martusewicz-Boros2, Katarzyna Modrzewska2, Elzbieta Radzikowska2, Kazimerz Roszkowski-Sliz2.   

Abstract

OBJECTIVES: Nasal carriage of Staphylococcus aureus and its superantigens (SAg) seem to be a risk factor disease exacerbation in granulomatosis with polyangiitis (GPA). We investigated the association between the presence of SAg in nasal swabs and activity of disease in GPA patients also taking into account correlation with an antimicrobial treatment.
METHODS: In a prospective study of a total of 150 GPA patients hospitalised in the period 2009-2016, nasal swabs were examined for the presence of Staphylococcus aureus and SAg. Subsequently, the association with disease activity was assessed.
RESULTS: Of 362 Staphylococcus aureus-positive nasal swab cultures from 115 of the 150 patients, the presence of at least one SAg in 126 samples (34.8%) from 56 patients (48.7%) was found. Among the 17 patients with limited to subglottic stenosis (SGS) disease, SAg were detected in 6 cases (35.3%). We did not find a significant correlation between the presence of SAg and disease activity (p=0.986), although when individual SAg were analysed separatively, SED and TSST-1 were more frequently present in active disease. Additionally, the results of the analysis demonstrated a protective effect of trimethoprim/sulfamethoxazole (T/S) treatment (0R 0.52, p<0.0092) in GPA patients. Interestingly, GPA limited to SGS appeared as an unfavourable factor associated with disease activity (0R 1.84, p=0.05).
CONCLUSIONS: The association between staphylococcal SAg in nasal swabs and GPA activity is not evident. Multiple mechanisms that may lead to disease activation still need to be investigated.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29745876

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  5 in total

1.  Antineutrophil cytoplasmic antibodies and their relationship with disease activity and presence of staphylococcal superantigens in nasal swabs in patients having granulomatosis with polyangiitis: results of a study involving 115 patients from a single center.

Authors:  Justyna Fijolek; E Wiatr; V Petroniec; E Augustynowicz-Kopec; M Bednarek; D Gawryluk; K Roszkowski-Sliz
Journal:  Clin Rheumatol       Date:  2019-07-23       Impact factor: 2.980

Review 2.  Staphylococcus aureus Nasal Carriage and Autoimmune Diseases: From Pathogenic Mechanisms to Disease Susceptibility and Phenotype.

Authors:  Fulvia Ceccarelli; Carlo Perricone; Giulio Olivieri; Enrica Cipriano; Francesca Romana Spinelli; Guido Valesini; Fabrizio Conti
Journal:  Int J Mol Sci       Date:  2019-11-11       Impact factor: 5.923

Review 3.  Antineutrophil cytoplasmic antibodies (ANCA) - their role in pathogenesis, diagnosis, and treatment monitoring of ANCA-associated vasculitis.

Authors:  Justyna FijoŁek; ElŻbieta Wiatr
Journal:  Cent Eur J Immunol       Date:  2020-07-09       Impact factor: 2.085

4.  Dynamic Changes in the Nasal Microbiome Associated With Disease Activity in Patients With Granulomatosis With Polyangiitis.

Authors:  Rennie L Rhee; Jiarui Lu; Kyle Bittinger; Jung-Jin Lee; Lisa M Mattei; Antoine G Sreih; Sherry Chou; Jonathan J Miner; Noam A Cohen; Brendan J Kelly; Hongzhe Lee; Peter C Grayson; Ronald G Collman; Peter A Merkel
Journal:  Arthritis Rheumatol       Date:  2021-07-31       Impact factor: 15.483

5.  IL-35 is critical in suppressing superantigenic Staphylococcus aureus-driven inflammatory Th17 responses in human nasopharynx-associated lymphoid tissue.

Authors:  Rong Xu; Rebecca K Shears; Ravi Sharma; Madhan Krishna; Christopher Webb; Richard Ali; Xiaoqing Wei; Aras Kadioglu; Qibo Zhang
Journal:  Mucosal Immunol       Date:  2020-01-02       Impact factor: 7.313

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.